Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: A randomised trial

European Journal of Endocrinology

Volumn 167, Issue 2, 2012, Pages 287-294

  Niskanen, Leo ^a,j   Leiter, Lawrence A ^b   Franek, Edward ^c   Weng, Jianping ^d   Damci, Taner ^e   Munt̃oz Torres, Manuel ^f   Donnet, Jean Paul ^g   Endahl, Lars ^h   TrineVang, Skjøth ^h   Vaag, Allan ⁱ  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^d SUN YAT SEN UNIVERSITY   (China)

^e ISTANBUL UNIVERSITY   (Turkey)

^f HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^g CHU Guadeloupe   (Guadeloupe)

^h NOVO NORDISK A S   (Denmark)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j CENTRAL FINLAND CENTRAL HOSPITAL   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN ASPART PLUS INSULIN DEGLUDEC; INSULIN DEGLUDEC; METFORMIN; UNCLASSIFIED DRUG;

ADULT; AGED; APPETITE; ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HUNGER; HYPOGLYCEMIA; LIPODYSTROPHY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; BIPHASIC INSULINS; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN ASPART; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; METFORMIN; MIDDLE AGED; SOLUBILITY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864331693     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0293     Document Type: Article

References (26)

1. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R & Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 32 193-203. (doi:10.2337/dc08- 9025)
2. Vaag A & Lund S. Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. European Journal of Endocrinology 2012 166 159-170. (doi:10.1530/EJE-11-0022)
3. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S & Levy JC. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. New England Journal of Medicine 2007 357 1716-1730. (doi:10.1056/NEJMoa075392)
4. Stehouwer MH, DeVries JH, Lumeij JA, Ader HJ, Engbers AM, Iperen AA, Snoek FJ & Heine RJ. Combined bedtime insulin - daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate - a randomised trial. Diabetes/Metabolism Research and Reviews 2003 19 148-152. (doi:10.1002/dmrr.356)
5. Malone JK, Kerr LF, Campaigne BN, Sachson RA & Holcombe JH. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, openlabel, crossover study in patients with type 2 diabetes beginning insulin therapy. Clinical Therapeutics 2004 26 2034-2044. (doi:10.1016/j.clinthera.2004.12.015)
6. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B & Garber A. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005 28 260-265. (doi:10.2337/diacare.28.2.260)
7. Kazda C, Hulstrunk H, Helsberg K, Langer F, Forst T & Hanefeld M. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. Journal of Diabetes and its Complications 2006 20 145-152. (doi:10.1016/j.jdiacomp.2005.09.004)
8. Wolffenbuttel BH, Klaff LJ, Bhushan R, Fahrbach JL, Jiang H & Martin S. Initiating insulin therapy in elderly patients with type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents. Diabetic Medicine 2009 26 1147-1155. (doi:10.1111/j.1464-5491.2009.02824.x)
9. Strojek K, Bebakar WM, Khutsoane DT, Pesic M, Smahelova A, Thomsen HF & Kalra S. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Current Medical Research and Opinion 2009 25 2887-2894. (doi:10.1185/03007990903354674)
10. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C & Wetterslev J. Intensive glycaemic control for patients with type 2 diabetes: systematic review with metaanalysis and trial sequential analysis of randomised clinical trials. BMJ 2011 343 d6898. (doi:10.1136/bmj.d6898)
11. Kurtzhals P, Heise T, Strauss HM, Bøttcher SG, Granhall C, Haahr H & Jonassen I. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia 2011 54 S426. (doi:10.1007/s00125-011-2276-4)
12. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Stryhn TK & Haahr H. Insulin degludec: less pharmacodynamic variability than insulin glargine under steady state conditions. Diabetologia 2010 53 S387. (doi:10.1007/s00125-010-1872-z)
13. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S & Haahr H. The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state. Diabetes 2011 60 A263. (doi:10.2337/db11-868-1281)
14. Nosek L, Heise T, Bøttcher SG, Hastrup H & Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect. Diabetologia 2011 54 S429. (doi:10.1007/s00125-011-2276-4)
15. Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, Lyby K, Jendle JH, Roberts AP, DeVries JH & Meneghini LF. Insulin degludec in type 1 diabetes a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011 34 661-665. (doi:10.2337/dc10-1925)
16. Garber A, King AB, Del Prato S, Sreenan S, Rosenstock J, Endahl LA, Francisco AMO & Hollander P. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012 379 1498-1507. (doi:10.1016/S0140-6736(12)60205-0)
17. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AMO, Pei H & Bode B. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012 379 1489-1497. (doi:10.1016/S0140-6736(12) 60204-9)
18. Jonassen I, Hoeg-Jensen T, Havelund S & Ribel U. Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co-formulation. Journal of Peptide Science 2010 16 32. (doi:10.1002/psc.1301)
19. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO & Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002 25 876-882. (doi:10.2337/diacare.25.5. 876)
20. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D & Zuckerman LA. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. Journal of Immunological Methods 2004 289 1-16. (doi:10.1016/j.jim.2004.06.002)
21. Bulsara MK, Holman CD, Davis EA & Jones TW. Evaluating risk factors associated with severe hypoglycaemia in epidemiology studies - what method should we use? Diabetic Medicine 2004 21 914-919. (doi:10.1111/j.1464-5491.2004. 01250.x)
22. Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F & Regulski M. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Experimental and Clinical Endocrinology & Diabetes 2006 114 527-532. (doi:10.1055/s-2006-949655)
23. Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S & Bech OM. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes, Obesity & Metabolism 2008 10 212-222. (doi:10.1111/j.1463-1326. 2007.00826.x)
24. Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M & Wenying Y. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. International Journal of Clinical Practice 2009 63 522-531. (doi:10.1111/j.1742-1241.2009.02002.x)
25. Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A, Romero E, Mersebach H, Dykiel P & Jorde R. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes a randomized, controlled trial. Diabetes Care 2011 34 669-674. (doi:10.2337/dc10-1905)
26. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, Zagar T & Poole CD. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010 375 481-489. (doi:10.1016/S0140-6736(09)61969-3)